FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... April 7, 2022 Fatiga relacionada con el cáncer: Lo que las personas con cáncer... March 2, 2021 Should Surgery And Radiation Be The Standard Treatment For DCIS? The... May 14, 2019 9 Ways To Teach Kids To Be Confident (Without Teaching Them... October 24, 2019 Load more HOT NEWS New on NCI’s Websites for October 2019 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney
